Immune status could determine efficacy of COVID-19 therapies.

Cully, Megan

Cully, Megan.

Nat Rev Drug Discov ; 19(7): 431-434, 2020 07.

Article in English | MEDLINE | ID: covidwho-601807

Subject(s)

Adjuvants, Immunologic/pharmacology; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Immunosuppressive Agents; Pandemics; Pneumonia, Viral; Anti-Inflammatory Agents/immunology; Anti-Inflammatory Agents/pharmacology; Antiviral Agents/immunology; Antiviral Agents/pharmacology; Betacoronavirus/drug effects; Betacoronavirus/physiology; COVID-19; Clinical Trials as Topic; Coronavirus Infections/epidemiology; Coronavirus Infections/immunology; Coronavirus Infections/therapy; Coronavirus Infections/virology; Cytokine Release Syndrome/immunology; Humans; Immunity, Cellular/drug effects; Immunosuppressive Agents/immunology; Immunosuppressive Agents/pharmacology; Inflammation Mediators; Interferon-beta/immunology; Interferon-beta/pharmacology; Interleukin-6/antagonists & inhibitors; Interleukin-6/immunology; Monitoring, Immunologic/methods; Pneumonia, Viral/epidemiology; Pneumonia, Viral/immunology; Pneumonia, Viral/therapy; Pneumonia, Viral/virology; SARS-CoV-2; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Adjuvants, Immunologic / Coronavirus Infections / Pandemics / Betacoronavirus / Immunosuppressive Agents / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Rev Drug Discov Journal subject: Pharmacology / Drug Therapy Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google